Raphael Pharmaceutical Inc.

For the period ended Dec 31, 2024. Filed Mar 31, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 31, 2025

RAPHStored price and day change unavailable

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 8. Consolidated Statements of Cash Flows

	Year Ended December 31,
2024 · 2023
Cash flows from operating activities
Net loss		$(1,519)		$(1,344	) **
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based payment in exchange for services		40		200
Share-based compensation		350		-
Depreciation		*	)	*	)
Changes in:
Other current assets		1		36
Related parties		190		35
Other accounts payables and accrued expenses		406		(130	) **
Net cash used in operating activities		(532)		(1,203)
Cash flows from investing activities
Purchase of fixed assets		-		-
Net cash provided by investing activities		-		-
Cash flows from financing activities
Receipt of a loan		41		-
Proceeds from issuance of common stock and warrants		280		1,145
Net cash provided by financing activities		321		1,145
Change in cash and cash equivalents		(211)		(58)
Cash and cash equivalents at the beginning of the year		230		288
Cash and cash equivalents at the end of the year		$19		$230
Non cash supplement
Issuance of shares for past services (Note 7i)	$	-		$200
Exercise of warrants (Note 7n)	$	-		$100

(*)	less than 1 thousand.

(**)	reclassified.

The accompanying notes are an integral part of the consolidated financial statements.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.